Top Page
Adherium Ltd.
(Sydney:ADR)
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Adherium Ltd. Business Overview & Revenue Model
Adherium Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 964.13K | 840.98K | 3.19M | 529.00K | 401.00K | 2.22M |
| Gross Profit | -246.95K | 267.70K | 1.69M | -690.00K | -789.00K | 677.00K |
| EBITDA | -12.44M | -11.56M | -9.91M | -12.65M | -12.74M | -8.46M |
| Net Income | -11.33M | -10.22M | -9.86M | -10.04M | -15.04M | -11.40M |
Balance Sheet | ||||||
| Total Assets | 4.87M | 9.89M | 12.68M | 8.53M | 17.04M | 6.72M |
| Cash, Cash Equivalents and Short-Term Investments | 387.21K | 6.20M | 9.08M | 5.28M | 15.18M | 4.58M |
| Total Debt | 752.96K | 93.20K | 44.00K | 85.00K | 0.00 | 0.00 |
| Total Liabilities | 3.46M | 3.41M | 3.47M | 3.00M | 3.00M | 3.33M |
| Stockholders Equity | 1.41M | 6.48M | 9.21M | 5.54M | 14.04M | 3.38M |
Cash Flow | ||||||
| Free Cash Flow | -11.18M | -10.61M | -9.32M | -9.89M | -11.30M | -7.46M |
| Operating Cash Flow | -11.17M | -10.61M | -9.28M | -9.61M | -11.27M | -7.32M |
| Investing Cash Flow | -14.70K | -37.00 | -41.00K | -279.00K | -29.00K | -138.00K |
| Financing Cash Flow | 8.40M | 7.73M | 13.07M | 0.00 | 21.90M | 11.34M |
Adherium Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | HK$15.54B | 5.61 | -7.44% | 4.07% | 11.55% | -28.15% | |
47 Neutral | AU$10.78M | ― | -375.15% | ― | -59.01% | 17.13% | |
45 Neutral | AU$4.42M | ― | -117.20% | ― | 2.91% | 13.51% | |
| €5.43M | ― | -321.94% | ― | ― | ― | ||
42 Neutral | AU$10.61M | ― | -98.08% | ― | -7.44% | 30.34% | |
41 Neutral | AU$10.79M | ― | -61.15% | ― | 35.63% | 18.55% | |
38 Underperform | AU$8.54M | ― | -191.40% | ― | ― | 19.74% |
Adherium Ltd. Corporate Events
Adherium Ltd. has announced that UBS Group AG and its related bodies corporate have become a substantial holder in the company as of July 7, 2025. UBS Group AG now holds a 12.13% voting power in Adherium Ltd., with significant shares held through its branches and associates, indicating a notable investment in the company.
Adherium Limited has announced a change in the interests of its substantial holder, Trudell Medical Limited. The change occurred due to the dilution of Trudell’s holdings following the issuance of new shares by Adherium. As a result, Trudell’s voting power in Adherium has decreased from 19.90% to 12.89%. This adjustment in voting power may impact Trudell’s influence over Adherium’s corporate decisions, potentially affecting its strategic direction and stakeholder interests.
Adherium Limited has experienced a change in the voting power of a substantial holder, Phillip Asset Management Ltd atf BioScience Managers Translation Fund I, due to the issuance of new shares. This change has resulted in a dilution of their holdings from 19.90% to 12.89%. This adjustment in voting power may impact the influence Phillip Asset Management has within the company, potentially affecting its strategic decisions and stakeholder dynamics.
Adherium Limited has announced an Investor Webinar to update the market on its Retail Entitlement Offer, which is open to eligible retail shareholders in Australia and New Zealand. The offer began on July 1, 2025, and will close on July 10, 2025. The webinar, scheduled for July 9, 2025, will feature a presentation by Non-Executive Director Kevin Gessner, providing important updates for shareholders and supporters. This initiative is part of Adherium’s ongoing efforts to engage with its stakeholders and provide transparency regarding its financial strategies.
FIL Limited has become a substantial holder in Adherium Limited, acquiring a 5.62% voting power through 77,982,072 common stock shares. This acquisition marks a significant investment by FIL Limited, potentially impacting Adherium’s market position and signaling confidence in the company’s future prospects.
Adherium Limited announced the cessation of 1,118,184 stock appreciation rights due to the expiry of options or other convertible securities without exercise or conversion as of June 30, 2025. This cessation may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth potential.
Adherium Ltd. has announced a change in the interests of its substantial holders, with Regal Funds Management Pty Limited and its associates increasing their voting power from 22.78% to 26.29%. This change reflects a strategic move by Regal Funds Management to strengthen its position within the company, potentially impacting Adherium’s governance and future strategic decisions.
Adherium Limited has announced the issuance of 488,479,082 unquoted securities, specifically options expiring on July 31, 2026. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
Adherium Limited announced the resolution of a delay in the allotment and issue of new shares and options under its Institutional Entitlement Offer, which was caused by a settlement issue with an overseas investor. The allotment is now scheduled for 3 July 2025, with no changes to the remaining timetable of the Entitlement Offer. This development ensures the continuation of the company’s fundraising efforts, potentially impacting its financial stability and market operations.
Adherium Limited has announced the opening of its accelerated non-renounceable entitlement offer to raise approximately $4.492 million. This offer is available to eligible shareholders and is part of the company’s strategy to strengthen its financial position and support future growth. The offer will close on July 10, 2025, with new shares and options expected to begin trading on July 18, 2025.
Adherium Limited announced an update regarding the issuance of securities to institutional investors, with the date now set for July 2, 2025. This accelerated non-renounceable entitlement offer aims to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities.
Adherium Limited has announced an update to a previous announcement regarding the issuance of securities. The update reflects an amendment to the number of securities to be issued, as detailed in a replacement prospectus lodged on June 26, 2025. This update pertains to an accelerated non-renounceable entitlement offer, commonly known as a JUMBO or ANREO. The announcement signifies a strategic move by Adherium to adjust its financial strategy, potentially impacting its market positioning and stakeholder interests.
Adherium Ltd. has announced an accelerated non-renounceable entitlement offer to raise approximately A$4.492 million. This offer allows eligible shareholders to purchase new shares and options, with the potential for additional bonus options if exercised by November 2025. The offer is partially underwritten and aims to enhance the company’s capital structure. The increased subscription amount reflects strong support from stakeholders, indicating potential positive impacts on Adherium’s market positioning and operational capabilities.
Adherium Limited has successfully closed the institutional component of its Accelerated Non-Renounceable Entitlement Offer, raising $4.492 million due to strong demand. The company is poised to enhance its market penetration in the U.S. healthcare sector, leveraging its smart inhaler technology to improve patient care and reduce costs. With commercial agreements in place and plans to expand its patient base, Adherium is set to capitalize on its innovative solutions in respiratory health.
Adherium Ltd. has announced a change in the interests of its substantial holder, Regal Funds Management Pty Limited and its associates. The change reflects an adjustment in the voting power and control over a significant number of ordinary shares, impacting the company’s shareholder structure and potentially influencing future corporate decisions.
Adherium Limited has announced a proposed issue of securities through an accelerated non-renounceable entitlement offer. This initiative involves issuing up to 800 million unlisted options over shares, exercisable at $0.005, with expiration dates in 2026. The offer aims to strengthen the company’s capital base and support its strategic growth initiatives, potentially impacting its market positioning and stakeholder interests.
Adherium Ltd. has announced a non-renounceable accelerated pro-rata entitlement offer to raise approximately A$4 million. This initiative aims to strengthen the company’s financial position and support its ongoing operations. The offer includes new shares and options for eligible shareholders, with PAC Partners Securities partially underwriting the offer. This capital raising effort is expected to bolster Adherium’s market positioning and provide additional resources for its strategic initiatives.
Adherium Limited is launching a partially underwritten accelerated non-renounceable entitlement offer to raise up to $4 million. The funds will be used to expand operations in the U.S., including hiring employees and contractors, recruiting a CEO, and general working capital. The initiative has received strong backing from major shareholders and venture capital funds, indicating confidence in Adherium’s growth strategy and its potential impact on the respiratory care market.
Adherium Limited has announced that K One W One Limited has become a substantial holder in the company, acquiring 66,836,248 ordinary shares, which represents a 7.44% voting power. This development indicates a significant investment and interest in Adherium, potentially impacting its market position and signaling confidence from investors in the company’s future prospects.
Adherium Ltd. has experienced a change in the interests of a substantial holder, Trudell Medical Limited, which has impacted the voting power associated with Adherium’s ordinary shares. This change in interest, including a share consolidation and entitlement offer, has adjusted Trudell Medical Limited’s voting power from 22.15% to 19.90%, reflecting a strategic shift in their investment position within Adherium.
Adherium Ltd. has experienced a change in the interests of a substantial holder, Phillip Asset Management Ltd atf BioScience Managers Translation Fund I. The fund increased its voting power in Adherium Ltd. from 16.32% to 19.90% through the voluntary conversion of convertible notes into ordinary shares, impacting the company’s shareholder structure.
Adherium Limited has announced the application for quotation of 140,293,872 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its market presence and operational capacity, potentially impacting its industry positioning and offering new opportunities for stakeholders.
Adherium Limited announced the issuance of 2,000,000 stock appreciation rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, reflecting the company’s strategy to incentivize and retain key personnel.
Adherium Limited announced a change in the director’s interest, with George Baran acquiring 1,200,000 convertible notes. This acquisition follows shareholder approval and reflects ongoing strategic financial maneuvers within the company, potentially impacting its market positioning and stakeholder interests.
Adherium Ltd. announced the issuance of 2,225,000 convertible notes, which are unquoted equity securities. This move is part of the company’s financial strategy to enhance its capital structure, potentially impacting its market position by providing additional resources for growth and development in the digital health sector.
Adherium Limited has announced a proposed issuance of 900,000 convertible notes, scheduled for November 10, 2025. This move is part of a strategic effort to raise capital, potentially impacting the company’s financial structure and market positioning, and offering new opportunities for stakeholders.
Adherium Limited has announced a successful capital raise of $900,000 through the issuance of convertible notes, supported by Phillip Asset Management Limited and Trudell Medical Limited. The funds will be used to further the roll-out of the Hailie® Smartinhaler® platform in the U.S. and for general working capital, potentially strengthening Adherium’s market position in digital health solutions for respiratory care.
Adherium Ltd. has announced the appointment of Keven Gessner as a director, effective May 8, 2025. As part of his role, Gessner holds 2,000,000 Stock Appreciation Rights, indicating a significant interest in the company’s future performance. This appointment is a strategic move that could influence Adherium’s market positioning and operational strategies, potentially impacting stakeholders positively by aligning leadership with shareholder interests.
Adherium Limited has announced that William Hunter has ceased to be a director of the company as of May 8, 2025. The notice details Hunter’s interests in the company’s securities, which include 174,170 fully paid ordinary shares. This change in directorship may impact the company’s governance and strategic direction, but specific implications for stakeholders or the company’s operations are not detailed in the announcement.
Adherium Limited has announced key leadership appointments to bolster its strategic marketing and sales efforts for the Hailie® Smartinhaler® platform in the US. The appointments include Keven Gessner as Non-Executive Director, Jason Hochman as Head of US Commercial/GTM, and David Haddad as Head of Product. These strategic hires aim to enhance Adherium’s market presence and accelerate its commercial growth in the US healthcare market, leveraging their extensive experience in digital health and respiratory care. The company’s recent capital raise of $2.6 million further supports its commitment to expanding its operations and driving the adoption of its technology.
Adherium Limited has reported significant growth in its US commercial patient base, with a more than 100% increase in the last quarter, reaffirming its target of 9,000 remote patient monitoring patients by the end of 2025. The company has expanded its US commercialization team and released a new Hailie Smartinhaler product compatible with AstraZeneca’s AIRSUPRA and Breztri Aerosphere, enhancing its market position and offering significant opportunities for growth. Strategic partnerships with Group Purchasing Organizations and other healthcare providers are expected to streamline adoption and drive further expansion, while the integration of AI-driven algorithms aims to improve patient adherence and care management.
Adherium Limited announced that all resolutions at their Extraordinary General Meeting were passed. These resolutions included the approval and ratification of the issuance of convertible notes to various entities, indicating a strategic move to enhance financial flexibility and potentially expand their market presence.